BofA analyst Jason Zemansky lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $7 from $8 and keeps a Buy rating on the shares, citing an updated cash position following the company’s Q3 update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics presents preclinical data on PREDATOR Platform
- Werewolf Therapeutics Reports Q3 2025 Financial Results
- Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)
- Werewolf Therapeutics’ WTX-330 Study: A Potential Game-Changer in Oncology
- Werewolf Therapeutics’ Promising Study on WTX-124 in Cancer Treatment